A Study of MORAb-009 in Subjects With Pancreatic Cancer, Mesothelioma, or Certain Types of Ovarian or Lung Cancer
Status:
Completed
Trial end date:
2008-09-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to establish the safest doses of an investigational drug called
MORAb-009 in subjects with pancreatic cancer, mesothelioma, or certain types of ovarian or
lung cancer. MORAb-009 is a monoclonal antibody that is directed to an antigen on the surface
of these cancers.